Please assess the completion status of the following clinical trial:

Trial Title: Estriol and Trimegestone Dose-response Trial With Single Dose Application of Vaginal Rings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Under treatment with a commercially available combined oral contraceptive containing 30 µg ethinylestradiol (EE) and 150 µg levonorgestrel (LVN) for the last 3 months prior to enrolment~* Body-mass index (BMI): ≥ 18.5 kg/m² and ≤ 30.0 kg/m²~* Good state of health~* Non-smoker, ex-smoker for at least 3 months~* Regular menstrual cycle with a length between 21 and 35 days~* Written informed consent, after having been informed about benefits and potential risks of the clinical trial~Exclusion Criteria:~* Existing diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the IMPs~* Subjects with severe allergies or multiple drug allergies~* Positive anti human immunodeficiency virus (anti-HIV) test, hepatitis B surface antigen (HBs-AG) test or anti hepatitis C virus (anti-HCV) test~* Presence or history of venous or arterial thrombosis, cerebrovascular accident, or increased risk of thrombosis~* Diabetes mellitus~* Unclarified vaginal bleeding or frequent infections of the urogenital tract~* Severe or chronic constipation~* Presence or history of migraine~* Drug or alcohol dependence~* Blood donation or other blood loss of more than 400 ml within the last 3 months~* Participation in a clinical trial during the last 6 months~* Pregnant or lactating women~* Subjects who do not agree to apply a barrier method for contraception

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Test 1 vaginal ring (Type: EXPERIMENTAL): Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days
- Test 2 vaginal ring (Type: EXPERIMENTAL): Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days
- Test 3 vaginal ring (Type: EXPERIMENTAL): Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).